Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorB. M. Greenwooden_US
dc.contributor.authorA. J. Hallen_US
dc.contributor.authorM. G. Roween_US
dc.contributor.authorH. C. Whittleen_US
dc.contributor.authorM. Georgeen_US
dc.contributor.authorA. A.K. Al-Ghassanien_US
dc.contributor.authorM. Elbualyen_US
dc.contributor.authorP. G. Malankaren_US
dc.contributor.authorA. J.M. Suleimanen_US
dc.contributor.authorG. B. Clementsen_US
dc.contributor.authorE. T. Hayen_US
dc.contributor.authorC. Nairnen_US
dc.contributor.authorM. H. Ridingen_US
dc.contributor.authorE. Bellen_US
dc.contributor.authorB. P. Hullen_US
dc.contributor.authorS. E. Robertsonen_US
dc.contributor.authorP. F. Wrighten_US
dc.contributor.authorH. Zoffmannen_US
dc.contributor.authorC. Areeen_US
dc.contributor.authorR. Samakosesen_US
dc.contributor.authorS. Simasathienen_US
dc.contributor.authorS. Migasenaen_US
dc.contributor.authorP. Pitisuttithamen_US
dc.contributor.authorB. Ponraten_US
dc.contributor.authorS. Tantivanichen_US
dc.contributor.authorS. Tharavanijen_US
dc.contributor.authorS. L. Cochien_US
dc.contributor.authorR. W. Linkinsen_US
dc.contributor.authorP. A. Patnarcaen_US
dc.contributor.authorR. W. Sutteren_US
dc.contributor.authorL. Andersonen_US
dc.contributor.authorK. Maheren_US
dc.contributor.authorM. Pallanschen_US
dc.contributor.authorS. Penarandaen_US
dc.contributor.otherMedical Research Council Laboratories Gambiaen_US
dc.contributor.otherMinistry of Health Omanen_US
dc.contributor.otherRuchill Hospitalen_US
dc.contributor.otherOrganisation Mondiale de la Santeen_US
dc.contributor.otherPramongkutklao Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNational Immunization Programen_US
dc.contributor.otherCenters for Disease Control and Preventionen_US
dc.identifier.citationBulletin of the World Health Organization. Vol.74, No.3 (1996), 253-268en_US
dc.description.abstractTo assess an immunization schedule combining oral (OPV) and inactivated poliovirus vaccines (IPV), we conducted a clinical trial in the Gambia, Oman, and Thailand. Children were randomized to receive one of the following schedules: OPV at birth, 6, 10, and 14 weeks of age; OPV at birth followed by both OPV and IPV at 6, 10, and 14 weeks of age; or placebo at birth followed by IPV at 6, 10, and 14 weeks of age. A total of 1685 infants were enrolled; 24-week serum specimens were available for 1291 infants (77%). Across the study sites at 24 weeks of age, the proportion of seropositive children in the combined schedule group was 95-99% for type 1, 99-100% for type 2, and 97-100% for type 3. In the Gambia and Oman, the combined schedule performed significantly better than OPV for type 1 (95-97% versus 88-90%) and type 3 (97-99% versus 72-73%). In the Gambia and Oman, seroprevalences in the IPV group were lower for type I (significantly lower in the Gambia); significantly lower for type 2; and significantly higher for type 3, compared with the OPV group. In Thailand, the IPV group had significantly lower proportions of children who were seropositive for each of the three types, compared with the OPV group. The responses to OPV in the Gambia, Oman, and Thailand were consistent with previous studies from these countries. IPV given at 6, 10, and 14 weeks of age provided inadequate serological protection against poliovirus, especially type 1. The combined schedule provided the highest levels of serum antibody response, with mucosal immunity equivalent to that produced by OPV alone.en_US
dc.rightsMahidol Universityen_US
dc.titleCombined immunization of infants with oral and inactivated poliovirus vaccines: Results of a randomized trial in the Gambia, Oman, and Thailanden_US
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.